

Evaluation of the Cytotoxic Effects of Ciprofloxacin on Human Glioblastoma A-172 Cell Line

Ashkan Zandi*, Taraneh Moini Zanjani**, Seyed Ali Ziai*,
Yalda Khazaei Poul*, Mostafa Haji Molla Hoseini**

*Department of Pharmacology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

**Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Abstract

Background: Glioblastoma multiforme, the most common, aggressive malignant brain tumor which affects patients of all ages, is principally resistant to treatment. Ciprofloxacin is an antibiotic that belongs to the fluoroquinolones. There are well-documented observations which indicate that ciprofloxacin has substantial anti-proliferative, apoptotic, cytotoxic and oxidative stress activities on various tumor cell lines.

Methods: We exposed the glioblastoma A-172 cell line to ciprofloxacin for 24, 48 and 72 h. Cytotoxicity was measured using MTT assay. The levels of Bax as an apoptotic and Bcl-2 as an anti-apoptotic protein were measured by ELISA and oxidative stress by the malondialdehyde assay.

Results: Ciprofloxacin induced tumor cell death in a dose-dependent manner with an IC_{50} value of 259.3 μ M at 72 h. We observed an increase in Bax levels, a decrease in Bcl-2 concentrations and increased Bax/Bcl-2 ratio under the influence of ciprofloxacin. Malondialdehyde levels, as an important marker of oxidative stress, increased in the human glioblastoma A-172 cell line.

Conclusion: These results indicated that ciprofloxacin had anti-tumor, cytotoxic and apoptotic effects in the human glioblastoma A-172 cell line which might be useful as an adjuvant added to a glioblastoma multiforme chemotherapeutic protocol in the future.

Keywords: Ciprofloxacin, Glioblastoma A-172 cell line, Cytotoxicity, Apoptosis, Oxidative stress

Corresponding Author:

Taraneh Moini Zanjani, PhD,
Department of Pharmacology,
School of Medicine, Shahid
Beheshti University of Medical
Sciences, Koodakyar St.,
Daneshjoo Blvd., Tehran, Iran
Tel: +98-2122439969
Fax: +98-2122439969
Email: tzanjani@yahoo.com

Introduction

Glioblastoma multiforme (GBM) is a highly lethal brain tumor (grade IV astrocytoma). Despite optimal treatment, which includes surgical

resection along with radiation and chemotherapy, patients have a median survival of only 12–15 months. Among several difficulties of current standard treatment of GBM

patients that include incomplete tumor removal, peritumoral edema, blood-brain barrier (BBB) disruption and inadequacy of maximum radiation dose for tumor destruction, the toxic adverse effects of chemo- or radiotherapy and drug resistance are the most important concerns.¹

Ciprofloxacin (CPF) is a quinolone antibiotic used against many bacterial infections.² It has been suggested that the 4-fluoroquinolones (FQs) target the bacterial enzyme DNA gyrase and also stabilize DNA strand breaks created by DNA gyrase and topoisomerase IV. However the FQs have lesser affinity to the eukaryotic DNA gyrase homologue, topoisomerase II. In general, at concentrations higher than average found in blood, inhibition of topoisomerase II can lead to the formation of stabilized cleavage complexes and the ultimate production of DNA double-strand breaks.³ In addition to the antibacterial activity of CPF, evidences have proven a substantial anti-proliferative activity among a variety of cancers such as bladder, colorectal, human prostate, osteosarcoma and leukemic cell lines.⁴⁻⁸

Apoptosis or programmed cell death, is a regulated physiological process essential for maintenance of cellular homeostasis. Apoptosis is a constitutive process that can be induced or inhibited by various stimuli. Recently, the pathogenesis of cancer, autoimmune and inflammatory diseases have been explained by the alteration of normal apoptosis regulation.⁹⁻¹² It was shown that some antibiotics could affect the life span of cells through apoptosis induction.^{6,13,14} Among numerous antibiotics, the effects of quinolones have been highlighted as the major contributor in this field.¹⁵⁻¹⁹ Ciprofloxacin as an anticancer agent, is used at concentrations higher than those to treat infectious diseases.²⁰ At these concentrations (200-300 µg/ml), CPF can effectively activate Bax, induce apoptosis of bladder carcinoma cells and yield to cell cycle arrest in the S/G2 stage.²¹ Oxidative stress that results from the generation of the free radicals is known to substantially contribute to several pathological conditions, aging, cardiovascular disorders, neurodegenerative and cancer

diseases.^{22,23} Evidences have revealed that CPF retains oxidative stress properties.

Based on previous researches, the overall goal of this study was to examine whether CPF could effectively reduce cell proliferation and can be added to GBM treatment protocols.

Materials and Methods

Drug and reagents

3-(4,5 dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) and dimethylsulfoxide (DMSO) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Trichloroacetic acid (TCA), thiobarbituric acid (TBA) and Coomassie® brilliant blue G-250 were purchased from Merck KGaA (Darmstadt, Germany). Ciprofloxacin hydrochloride was purchased from Daroupakhsh Pharmaceutical Co., Ltd. (Tehran, Iran).

Cell culture

We cultured the human glioblastoma A-172 cell line (Avicenna Research Institute, Tehran, Iran) in RPMI 1640 medium supplemented with 10% heat inactivated fetal bovine serum (FBS) and penicillin/streptomycin (100 µg/ml). Cells were grown at 37°C in a humidified atmosphere of 5% CO₂ and 95% air. They were harvested and used at the exponential phase of growth for cytotoxicity evaluation.

Cytotoxicity assay

The stock solution used in this study was 2.5 mM CPF in cell culture medium. A-172 cells were seeded into cell culture 96-well plates at 1×10^4 cells/well that contained 200 µl of cell culture medium and incubated at 37°C for 24 h in a 5% CO₂ atmosphere. Next, the medium was removed and replaced by fresh cell culture medium that contained different concentrations of CPF (2073.5, 1036.7, 518.3, 259.1, 129.5, 64.7, 32.3, and 16.1 µM) added in triplicate. After 24, 48 and 72 h, we added 100 µl MTT (1 mg/ml) to each well, followed by further incubation for 4 h. After the incubation time, the cell culture medium was removed and 100 µl DMSO was added to solubilize the formazan crystals formed during the

MTT assay. A solution of DMSO and cell culture medium was used for the control treatment. The absorbance was measured using a microplate reader (ELX 800 Biotek, USA) at 530 nm.

Enzyme-linked immunosorbent assay (ELISA) for apoptotic proteins

The cells were suspended in cell culture medium, seeded (1×10^6 cells) into culture plates and incubated in a humidified atmosphere of 5% CO₂ for 24 h until adherence. We added CPF ($1/2 IC_{50}$, IC_{50} and $2 IC_{50}$) in triplicate to assess the apoptotic effects on the A-172 cell line. After 72 h, the cells were harvested. Next, we prepared the samples according to the ELISA manufacturer's information, then used the supernatant to measure the levels of Bax as an apoptotic protein and Bcl-2 as an anti-apoptotic protein with the Bax and Bcl-2 ELISA kits (Zellbio®, Germany), respectively. The absorbance was measured at 450 nm.

Malondialdehyde (MDA) assay

The malondialdehyde (MDA) levels, as an indicator of oxidative stress, were measured according to the Placer method. Briefly, samples were precipitated with a mixture of TCA and TBA and boiled. The supernatant was collected and we measured absorbance at 535 nm.²⁴ Protein concentration was measured according to the Bradford method. Coomassie® Brilliant Blue G-250 dye binds to proteins, the dye has both a blue and a red form. When this dye binds to a protein, the red form is converted to the blue form. The absorption was measured by a microplate reader (ELX 800 Biotek, USA) at 595 nm.²⁵

Statistical analysis

All data were expressed as mean \pm standard deviation (SD). Statistical significance was set at $P < 0.05$. Graph Pad Prism 6.01 (GraphPad Software, Inc., USA) was used to analyze the drug effects. Data were analyzed using one-way analysis of variance (ANOVA) and the Tukey test, and were calculated using SPSS 21.0 (IBM, Armonk, NY).

Results

Cytotoxic effects of ciprofloxacin (CPF) treatment on the A-172 cell line

Ciprofloxacin produced significant, dose-dependent cell death after 24, 48 and 72 h exposure in the A-172 cell line. The half maximal inhibitory concentrations (IC_{50}) were found to be 388.6 μ M (24 h), 308.9 μ M (48 h) and 259.3 μ M (72 h). We considered 259.3 μ M at 72 h as the IC_{50} for more potency than the other IC_{50} values. No statistical significance existed between IC_{50} values ($P > 0.05$; Figure 1).

Apoptotic protein (Bax) analysis

Protein analysis by ELISA revealed a dose-dependent increase in Bax levels in the A-172 cell line after 72 h exposure of CPF compared to the control group ($P < 0.001$; Figure 2A).

Anti-apoptotic (Bcl-2) protein analysis

Protein analysis by ELISA showed a dose-dependent decrease in Bcl-2 levels in the A-172 cell line after 72 h exposure of CPF compared to the control group ($P < 0.001$; Figure 2B).

Bax/Bcl-2 ratio analysis

We observed a dose-dependent increase in Bax/Bcl-2 ratio in the A-172 cell line after 72 h exposure of CPF compared to the control group ($P < 0.001$; Figure 2C).




Figure 1. The effects of ciprofloxacin (CPF) treatment on proliferation of the A-172 cell line. Cells were grown in 96-well plates and treated with CPF at different concentrations for 24, 48 and 72 h. Values are represented by mean \pm SD.

Analysis of the malondialdehyde (MDA) assay

Ciprofloxacin increased the MDA levels after 72 h exposure in A-172 cell line in a dose-dependent manner compared to the control group ($P < 0.001$; Figure 3).

Discussion

In this study, we assessed the effects of CPF on human glioblastoma A-172 cancer cell line. We found that CPF had the ability to produce cytotoxicity in a dose-dependent manner. The IC_{50} value was considered to be 259.3 μ M at 72 h. The drug had apoptotic effects on this cell line. Ciprofloxacin increased the levels of Bax (IC_{50} increased 8 times compared to the control group), MDA (IC_{50} increased 7.5 times compared to the control group), Bax/Bcl-2 ratio (IC_{50} increased 10 times compared to the control group) and decreased the level of Bcl-2 (IC_{50} decreased to 37% compared to the control group; $P < 0.001$).

In vitro studies showed the cytotoxic properties of CPF on numerous cell lines such as the bladder carcinoma cell line, Jurkat T cell leukemia cell line, hormone-refractory prostate cancer (HRPC) cell lines. In addition, two transitional cell carcinoma cell lines; MBT-2 and T24, as well as sarcoma, osteosarcoma, colorectal carcinoma, GL26 murine glioma and CHOAA8 ovarian cell lines were also affected.^{2,4,26-31} Ciprofloxacin inhibited tumor cell proliferation, increased population doubling time, and reduced saturation density of the cells.³² Ciprofloxacin has been shown to inhibit mitochondrial topoisomerase II, thus affecting cellular energy metabolism. Administration of 25 μ g/ml of CPF inhibited the proliferation of Jurkat cells, whereas concentrations that exceeded 80 μ g/ml could induce apoptosis. The inhibition of Jurkat cell proliferation by CPF was seen in the G2/M phase of the cell cycle which compromised the formation of mitotic spindle and induced aneuploidy.² The current study data supported the results of the above mentioned studies on the cytotoxic effects of CPF in cancer cell lines.

However, CPF displays anti-proliferative and




Figure 2. The effects of ciprofloxacin (CPF) treatment on level of apoptotic factors of the A-172 cell line after 72 h. (A) Bax, (B) Bcl-2 and (C) Bax/Bcl-2 ratio. Values are represented by mean \pm SD. ***: $P < 0.001$ compared to the control group; †††: $P < 0.001$.

apoptotic effects, which is seen in malignant but not normal cells.² Aranha et al. have stated that CPF induces anti-proliferative and apoptotic activity on prostate cancer cells (PC-3) but not on non-tumorigenic prostate epithelial cells (MLC8891). This finding suggests that CPF could probably be used as a possible adjuvant for tumor therapy without adverse effects on normal cells.⁴

Studies have reported anti-proliferative and apoptotic activities of CPF in tumor cell lines mediated by cell cycle arrest at the S-G2/M phase. Bax translocation to mitochondrial membrane leads to an increase in the Bax/Bcl-2 ratio in some cancer cells such as PC-3 prostate cancer cells.⁴ Fluoroquinolone antibiotics may also trigger the Bax-pathway of apoptosis or interfere directly with mitochondrial membrane proteins.^{33,34} Researches have shown that CPF triggered apoptotic cell death. This might be attributed to the up-regulation of Bax which altered the Bax/Bcl-2 ratio in favor of apoptosis.⁶ Results of this study showed that CPF has apoptotic effects on the A-172 cell line. Ciprofloxacin increased Bax levels to 339% (1/2 IC₅₀), 402% (IC₅₀) and 491% (2 IC₅₀) compared to the control group ($P<0.001$). It also increased the Bax/Bcl-2 ratio to 395% (1/2 IC₅₀), 543% (IC₅₀) and 798% (2 IC₅₀) compared to the control group ($P<0.001$). Bcl-2 levels decreased to 43% (2 IC₅₀), 37% (IC₅₀) and 30% (1/2 IC₅₀) compared to the control group ($P<0.001$). All increases and decreases were dose-dependent.

An imbalance between intracellular production of free radicals and the cellular defense mechanisms results in increased oxidative stress. One of the manifestations of oxidative stress is lipid peroxidation which has been known to play an important role in the toxicity of many drugs.³⁵ Lipid peroxidation is a significant determinant of the degree of free radical generation with MDA being one of the products, as well as an important marker of the process of the oxidative stress.³⁶⁻³⁸ Possibly, the generation of ROS may occur during oxidative metabolism of FQs, notably CPF.³⁹ The previous studies have reported that the generation

of ROS by FQs resulted in cellular damage.^{40,41} Ciprofloxacin increased MDA concentrations in the livers of rats, which indicated increased lipid peroxidation and promotion of oxidative stress.⁴² Results of this study showed that CPF increased the MDA levels to 182% (1/2 IC₅₀), 375% (IC₅₀) and 671% (2 IC₅₀) compared to the control group in a dose-dependent manner ($P<0.001$).

Various mechanisms are involved in the beneficial effects of CPF due to its anti-microbial activities on cancer patients who undergo chemotherapy.²⁹ One of these mechanisms is immune modulation which protects patients against new infections by reductions in cytokine production and improvements in immune response to infections normally found in cancer patients.^{43,44} Another mechanism is based on the action of quinolones on hematopoiesis. Quinolones, particularly CPF, by means of a cyclopropyl moiety at position N1 has been shown to increase the production of colony-stimulating factors, myeloid progenitors, hemoglobin, white blood cells (lessen neutropenia) and increase the survival of cyclophosphamide-treated mice. This finding was similar to data obtained when granulocyte colony-stimulating factor were used in these mice.^{29,45} Finally, the quinolone anti-tumor effects mediated by inhibition of mammalian DNA polymerase, topoisomerases I and II, were




Figure 3. The effects of ciprofloxacin (CPF) treatment on level of malondialdehyde (MDA) of the A-172 cell line after 72 h. Values are represented by mean \pm SD.; ***: $P<0.001$ compared to the control group; †††: $P<0.001$.

considered other CPF effects in cancer treatment.²⁹ Quinolones could probably reduce the mortality rate among cancer patients. Additional data have reported the use of FQs with chemotherapeutic agents in several human cancer cell lines; including head and neck, colon, prostate cancers and hepatocellular carcinoma.⁴⁶⁻⁴⁹ In these experiments, CPF either sensitized multi-drug resistant cancer cells to chemotherapy or increased the efficacy of the chemotherapeutic agents.⁴⁷⁻⁴⁹ In our previous study, we have reported the synergistic effects of the combination of CPF and temozolomide on the human glioblastoma A-172 cell line.⁵⁰

We showed that CPF increased MDA levels and produced oxidative stress in the human glioblastoma A-172 cancer cell line. This drug showed cytotoxic and apoptotic effects. It increased Bax levels, increased the Bax/Bcl-2 ratio and decreased Bcl-2 levels in the cell line which supported findings from previous studies.

Conclusion

Ciprofloxacin can be used as an adjuvant to treat GBM by increasing apoptosis and ROS production in these cells.

Acknowledgement

This article has been extracted from the thesis written by Ashkan Zandi, PhD candidate of Pharmacology, Shahid Beheshti University of Medical Sciences (Registration No: 165). The authors would like to thank Hadi Kalantar for his kind collaboration.

The present article is financially supported by the Research Department of the School of Medicine, Shahid Beheshti University of Medical Sciences (Grant No: 6132).

Conflict of interest

No conflict of interest is declared.

References

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. *N Engl J Med*. 2005;352(10):987-96.
2. Koziel R, Szczepanowska J, Magalska A, Piwocka K, Duszynski J, Zablocki K. Ciprofloxacin inhibits proliferation and promotes generation of aneuploidy in Jurkat cells. *J Physiol Pharmacol*. 2010;61(2):233-9.
3. Burden DA, Osheroff N. Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme. *Biochim Biophys Acta*. 1998;1400(1-3):139-54.
4. Aranha O, Grignon R, Fernandes N, McDonnell TJ, Wood DP Jr, Sarkar FH. Suppression of human prostate cancer cell growth by ciprofloxacin is associated with cell cycle arrest and apoptosis. *Int J Oncol*. 2003;22(4):787-94.
5. Aranha O, Zhu L, Alhasan S, Wood DP Jr, Kuo TH, Sarkar FH. Role of mitochondria in ciprofloxacin induced apoptosis in bladder cancer cells. *J Urol*. 2002;167(3):1288-94.
6. Herold C, Ocker M, Ganslmayer M, Gerauer H, Hahn EG, Schuppan D. Ciprofloxacin induces apoptosis and inhibits proliferation of human colorectal carcinoma cells. *Br J Cancer*. 2002;86(3):443-8.
7. Miclau T, Edin ML, Lester GE, Lindsey RW, Dahners LE. Effect of ciprofloxacin on the proliferation of osteoblast-like MG-63 human osteosarcoma cells *in vitro*. *J Orthop Res*. 1998;16(4):509-12.
8. Somekh E, Douer D, Shaked N, Rubinstein E. *In vitro* effects of ciprofloxacin and pefloxacin on growth of normal human hematopoietic progenitor cells and on leukemic cell lines. *J Pharmacol Exp Ther*. 1989;248(1):415-8.
9. Andreoli TE. The apoptotic syndromes. *Am J Med*. 1999;107(5):488.
10. Raff M. Cell suicide for beginners. *Nature*. 1998;396(6707):119-22.
11. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. *Science*. 1995;267(5203):1456-62.
12. Woodle ES, Kulkarni S. Programmed cell death. *Transplantation*. 1998;66(6):681-91.
13. Dearstyne EA, Kerkvliet NI. Mechanism of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-induced decrease in anti-CD3-activated CD4(+) T cells: the roles of apoptosis, Fas, and TNF. *Toxicology*. 2002;170(1-2):139-51.
14. Labro MT. Interference of antibacterial agents with phagocyte functions: immunomodulation or "immunofairy tales"? *Clin Microbiol Rev*. 2000;13(4):615-50.
15. Kawasaki S, Takizawa H, Ohtoshi T, Takeuchi N, Kohyama T, Nakamura H, et al. Roxithromycin inhibits cytokine production by and neutrophil attachment to human bronchial epithelial cells *in vitro*. *Antimicrob Agents Chemother*. 1998;42(6):1499-502.
16. Khan A, Slifer TR, Remington JS. Effect of trovafloxacin on production of cytokines by human monocytes. *Antimicrob Agents Chemother*. 1998;42(7):1713-7.

17. Ono Y, Ohmoto Y, Ono K, Sakada Y, Murata K. Effect of grepafloxacin on cytokine production *in vitro*. *J Antimicrob Chemother*. 2000;46(1):91-4.
18. Riesbeck K, Forsgren A. Limited effects of temifloxacin compared with ciprofloxacin on T-lymphocyte function. *Antimicrob Agents Chemother*. 1994;38(4):879-82.
19. Vazifeh D, Bryskier A, Labro MT. Effect of proinflammatory cytokines on the interplay between roxithromycin, HMR 3647, or HMR 3004 and human polymorphonuclear neutrophils. *Antimicrob Agents Chemother*. 2000;44(3):511-21.
20. Smart DJ, Halicka HD, Traganos F, Darzynkiewicz Z, Williams GM. Ciprofloxacin-induced G2 arrest and apoptosis in TH6 lymphoblastoid cells is not dependent on DNA double-strand break formation. *Cancer Biol Ther*. 2008;7(1):113-9.
21. Aranha O, Wood DP Jr, Sarkar FH. Ciprofloxacin mediated cell growth inhibition, S/G2-M cell cycle arrest, and apoptosis in a human transitional cell carcinoma of the bladder cell line. *Clin Cancer Res*. 2000;6(3):891-900.
22. Sun AY, Chen YM. Oxidative stress and neurodegenerative disorders. *J Biomed Sci*. 1998;5(6):401-14.
23. Abuja PM, Albertini R. Methods for monitoring oxidative stress, lipid peroxidation and oxidation resistance of lipoproteins. *Clin Chim Acta*. 2001;306(1-2):1-17.
24. Placer ZA, Cushman LL, Johnson BC. Estimation of product of lipid peroxidation (malondialdehyde) in biochemical systems. *Anal Biochem*. 1966;16(2):359-64.
25. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye-binding. *Anal Biochem*. 1976;72:248-54.
26. Zehavi-Willner T, Shalit I. The inhibitory effect of ciprofloxacin on proliferation of a murine bladder carcinoma cell line. *J Antimicrob Chemother*. 1992;29(3):323-8.
27. Pinto AC, Moreira JN, Simões S. Ciprofloxacin sensitizes hormone-refractory prostate cancer cell lines to doxorubicin and docetaxel treatment on a schedule-dependent manner. *Cancer Chemother Pharmacol*. 2009;64(3):445-54.
28. Ebisuno S, Inagaki T, Kohjimoto Y, Ohkawa T. The cytotoxic effects of fleroxacin and ciprofloxacin on transitional cell carcinoma *in vitro*. *Cancer*. 1997;80(12):2263-7.
29. Paul M, Gafter-Gvili A, Fraser A, Leibovici L. The anti-cancer effects of quinolone antibiotics. *Eur J Clin Microbiol Infect Dis*. 2007;26(11):825-31.
30. Kloskowski T, Olkowska J, Nazlica A, Drewa T. The influence of ciprofloxacin on hamster ovarian cancer cell line CHO AA8. *Acta Pol Pharm*. 2010;67(4):345-9.
31. Esmailzadeh A, Ebtekar M, Biglari A, Zuhair M. Influence of ciprofloxacin on glioma cell line GL26: A new application for an old antibiotic. *Afric J Microb Res*. 2012;6(23):4891-6.
32. Mondal ER, Das SK, Mukherjee P. Comparative evaluation of antiproliferative activity and induction of apoptosis by some fluoroquinolones with a human non-small cell lung cancer cell line in culture. *Asian Pac J Cancer Prev*. 2004;5(2):196-204.
33. Mancini M, Anderson BO, Caldwell E, Sedghinasab M, Paty PB, Hockenbery DM. Mitochondrial proliferation and paradoxical membrane depolarization during terminal differentiation and apoptosis in a human colon carcinoma cell line. *J Cell Biol*. 1997;138(2):449-69.
34. Jurgensmeier JM, Xie Z, Deveraux Q, Ellerby L, Bredesen D, Reed JC. Bax directly induces release of cytochrome c from isolated mitochondria. *Proc Natl Acad Sci U S A*. 1998;95(9):4997-5002.
35. Buyukokuroglu ME, Cemek M, Yurumez Y, Yavuz Y, Aslan A. Antioxidative role of melatonin in organophosphate toxicity in rats. *Cell Biol Toxicol*. 2008;24(2):151-8.
36. Halliwell B, Gutteridge JM. Lipid peroxidation, oxygen radicals, cell damage, and antioxidant therapy. *Lancet*. 1984;1(8391):1396-7.
37. Valenzuela A. The biological significance of malondialdehyde determination in the assessment of tissue oxidative stress. *Life Sci*. 1991;48(4):301-9.
38. Chaudière J, Ferrari-Iliou R. Intracellular antioxidants: from chemical to biochemical mechanisms. *Food Chem Toxicol*. 1999;37(9-10):949-62.
39. Sorgel F. Metabolism of gyrase inhibitors. *Rev Infect Dis*. 1989;11 Suppl 5:S1119-29.
40. Dhamidharka VR, Nadeau CL, Cannon HW, Harris HW, Rosen S. Ciprofloxacin overdose: acute renal failure with prominent apoptotic changes. *Am J Kidney Dis*. 1998;31(4):710-2.
41. Pouzauaud F, Dutot M, Martin C, Debray M, Warnet JM, Rat P. Age-dependent effects on redox status, oxidative stress, mitochondrial activity and toxicity induced by fluoroquinolones on primary cultures of rabbit tendon cells. *Comp Biochem Physiol C Toxicol Pharmacol*. 2006;143(2):232-41.
42. Afolabi OK, Oyewo EB. Effects of ciprofloxacin and levofloxacin administration on some oxidative stress markers in the Rat. *Int J Biol Biomol Agri Food Biotech Eng*. 2014;8(1):72-6.
43. Dalhoff A, Shalit I. Immunomodulatory effects of quinolones. *Lancet Infect Dis*. 2003;3(6):359-71.
44. Dalhoff A. Immunomodulatory activities of fluoroquinolones. *Infection*. 2005;33 Suppl 2:55-70.
45. Riesbeck K, Forsgren A. Selective enhancement of synthesis of interleukin-2 in lymphocytes in the presence of ciprofloxacin. *Eur J Clin Microbiol Infect Dis*. 1990;9(6):409-13.

46. Norris MD, Madafiglio J, Gilbert J, Marshall GM, Haber M. Reversal of multidrug resistance-associated protein-mediated drug resistance in cultured human neuroblastoma cells by the quinolone antibiotic difloxacin. *Med Pediatr Oncol.* 2001;36(1):177-80.
47. Herold C, Ganslmayer M, Ocker M, Blauburger S, Zopf S, Hahn EG, et al. Overadditive anti-proliferative and pro-apoptotic effects of a combination therapy on colorectal carcinoma cells. *Int J Oncol.* 2003;23(3):751-6.
48. El-Rayes BF, Grignon R, Aslam N, Aranha O, Sarkar FH. Ciprofloxacin inhibits cell growth and synergises the effect of etoposide in hormone resistant prostate cancer cells. *Int J Oncol.* 2002;21(1):207-11.
49. Fu Y, Zhou S, Li D, Zhang Y, Li S, Li C. Ciprofloxacin inhibits proliferation and synergistic effect against hepatocellular carcinoma cancer lines with cisplatin. *Afric J Pharmacy Pharmacol.* 2013;7(26):1793-801.
50. Zandi A, Moini Zanjani T, Ziai SA, Khazaei Poul Y, Haji Molla Hoseini M. The synergistic effects of the combination of ciprofloxacin and temozolomide on human glioblastoma A-172 cell line. *Middle East J Cancer.* 2017;8(1):31-8.